SAMiRNA-AREG was developed and tested in pulmonary disease models, such as bleomycin-induced pulmonary fibrosis and transforming growth factor-beta (TGF-β) transgenic mouse models23. Here, TGFB1 is linked to pulmonary fibrosis.